Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Padeliporfin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 24 Jan 2019 Planned End Date changed from 1 Mar 2024 to 15 Dec 2025.
- 24 Jan 2019 Planned primary completion date changed from 1 Mar 2019 to 15 Dec 2020.
- 31 Aug 2018 Biomarkers information updated